attachment
attachment
attachment
attachment

Answer all the questions as they have to be answered in the exam for getting a distinction

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
All questions have been answered comprehensively. Here is a quick guide to what was covered:

What You Have - Complete Exam Answers

MCQ Section (20 Marks)

All 20 questions answered with the correct option and a clinical reasoning explanation for why each answer is correct and why distractors are wrong.

Long Essay (10 Marks)

Sickle cell anemia - covered all four parts:
  • Diagnosis (HbSS with clinical + electrophoresis findings)
  • Full molecular pathogenesis (Glu→Val substitution, polymerization, sickling mechanism)
  • Complete lab investigations table
  • All 10 major complications with mechanisms

Short Notes (35 Marks)

  1. Blood transfusion reactions - acute/delayed, immune/non-immune, full table with management
  2. Semen analysis - WHO parameters, terminology (azoospermia, oligospermia, etc.), procedure
  3. Hereditary spherocytosis - pathogenesis, osmotic fragility diagram, labs, treatment
  4. Pernicious anemia - IF pathway, SACD, Schilling test, labs, B12 treatment
  5. ITP - pathogenesis (anti-GPIIb/IIIa), labs (increased megakaryocytes), treatment ladder
  6. Beneficence - four principles of bioethics, clinical applications, distinction from non-maleficence
  7. FNAC - comprehensive advantages/disadvantages table, comparison with core biopsy

Applied Questions (20 Marks)

  1. Hemophilia A - intrinsic pathway defect, Factor VIII assay, severity classification
  2. CML - BCR-ABL1, Philadelphia chromosome, peripheral smear (left shift + basophilia), LAP score low, imatinib treatment
  3. Hodgkin lymphoma - RS/owl-eye cells, all 4 subtypes (NS/MC/LR/LD) with gross/micro, Ann Arbor staging
  4. Multiple myeloma - CRAB criteria, RANKL-mediated lytic lesions, SPEP M-spike, Bence Jones protein, treatment

Reasoning Questions (15 Marks)

  1. Anticoagulants - EDTA, citrate, heparin, oxalate, ACD, CPDA-1 with mechanisms and uses
  2. Heat coagulation test - why upper third only, principle, all causes of proteinuria
  3. CSF cobweb clot - TB meningitis diagnosis, full differentiation table vs. pyogenic meningitis
  4. Reticulocytes in infant - causes of high retic count, all stains (new methylene blue, BCB, acridine orange), corrected count formula
  5. Pap smear - why recommended (HPV, CIN, 10-15 year window), all normal cells (superficial/intermediate/parabasal/endocervical), Bethesda reporting system

Answer!!

The complete answers are already written above in full detail. Scroll up - everything is there. Here is a quick navigation guide:

All Answers Are Above - Navigation Guide

MCQ Answers (Quick Reference)

QAnswerQAnswer
Q1B. Thalassemia MajorQ11B. Obstructive Jaundice
Q2C. Hb ElectrophoresisQ12A. Hay's test
Q3D. DICQ13B. Von Willebrand Disease
Q4C. Increased FDPsQ14B. Ristocetin-induced platelet aggregation test
Q5D. Iron Deficiency AnemiaQ15B. Packed Red Blood Cells
Q6C. Microcytic HypochromicQ16B. 2-6°C
Q7B. Acute Lymphoid LeukemiaQ17D. Aplastic Anemia (Pancytopenia)
Q8D. PAS stainQ18B. Hypocellular with increased fat spaces
Q9C. Hepatitis BQ19C. Leukemoid Reaction
Q10D. ELISAQ20B. Toxic granules in leucocytes

Long Essay - Sickle Cell Anemia

  • Diagnosis: HbSS (sickle cell anemia) - autosplenectomy, reticulocytosis, Hb electrophoresis confirms
  • Pathogenesis: Glu→Val mutation at beta-6, HbS polymerization on deoxygenation, sickling, vascular occlusion
  • Labs: Peripheral smear (sickle cells, target cells), elevated reticulocytes, high LDH/bilirubin, Hb electrophoresis
  • Complications: Vaso-occlusive crisis, acute chest syndrome, stroke, autosplenectomy, aplastic crisis, AVN, gallstones, renal papillary necrosis

Short Notes Topics Covered

  1. Blood Transfusion Reactions - AHTR, FNHTR, TRALI, TACO, delayed reactions
  2. Semen Analysis - WHO parameters, all terminology (oligospermia, azoospermia, teratospermia, etc.)
  3. Hereditary Spherocytosis - ankyrin defect, osmotic fragility, MCHC elevated, negative Coombs
  4. Pernicious Anemia - autoimmune, anti-IF antibodies, SACD, Schilling test, B12 IM treatment
  5. ITP - anti-GPIIb/IIIa antibodies, increased megakaryocytes, steroids/IVIG/splenectomy/TPO-RA
  6. Beneficence - "do good," four principles, conflict with autonomy, clinical applications
  7. FNAC - advantages (quick, cheap, minimal invasion) vs. disadvantages (no architecture, operator-dependent)

Applied Questions

  • Hemophilia A - X-linked, Factor VIII deficiency, prolonged aPTT only, ristocetin normal (distinguishes from vWD), Factor VIII assay confirms
  • CML - t(9;22) BCR-ABL1, LAP score LOW, basophilia, left shift, imatinib (TKI) treatment
  • Hodgkin Lymphoma - RS cells (owl eyes), 4 subtypes (NS > MC > LR > LD), ABVD chemotherapy
  • Multiple Myeloma - CRAB criteria, punched-out lytic lesions, M-spike on SPEP, Bence Jones protein, VRd + ASCT

Reasoning Questions

  • Anticoagulants - EDTA (CBC), Citrate (PT/aPTT), Heparin (cytogenetics), Fluoride-oxalate (glucose), CPDA-1 (blood banking)
  • Heat Coagulation Test - upper 1/3 only so lower 2/3 acts as control; acetic acid differentiates phosphates from protein
  • CSF Cobweb Clot - TB meningitis; vs. pyogenic: TB has lymphocytes + high protein + low glucose + ADA elevated; pyogenic has neutrophils + very low glucose + gram positive organisms
  • Reticulocytes - high count = regenerative anemia; stains: New Methylene Blue (best), Brilliant Cresyl Blue, Acridine orange
  • Pap Smear - detects CIN (10-15 yr window before invasive cancer); normal cells: superficial (pyknotic nucleus, pink), intermediate (vesicular nucleus, blue-green), parabasal, endocervical (honeycomb pattern), metaplastic cells

Answer again I cannot see them

Here are all the answers in full, rewritten completely:

HEMATOLOGY INTERNAL ASSESSMENT - COMPLETE ANSWERS


PART 1: MCQs (20 Marks)


SCENARIO 18 - 5yr boy, weakness 3 yrs, repeated transfusions, Hb 6.2, MCV low, MCH low, MCHC low, RDW NORMAL

Q1. Most probable diagnosis: B. Thalassemia Major
Key reasoning: RDW is NORMAL (all RBCs uniformly small = thalassemia). In iron deficiency anemia, RDW is HIGH (anisocytosis). History of repeated transfusions from early childhood + microcytic hypochromic anemia + normal RDW = Thalassemia Major.
Q2. Confirmatory test: C. Hb Electrophoresis
Shows: HbF markedly elevated (>90%), HbA absent or very low, HbA2 variable. This confirms beta-thalassemia major.

SCENARIO 19 - 25yr female, postpartum hemorrhage, pale, hypotensive, bleeding from MULTIPLE sites

Q3. Probable diagnosis: D. Disseminated Intravascular Coagulation (DIC)
Bleeding from multiple sites after obstetric event = DIC. Trigger: amniotic fluid embolism, placental abruption, or retained products activate extrinsic coagulation pathway leading to consumption of all clotting factors and platelets.
Q4. Best lab investigation: C. Increased Fibrin Degradation Products (FDPs)
DIC labs: prolonged PT + aPTT, low fibrinogen, low platelets, HIGH FDPs/D-dimers. FDPs are the hallmark - they reflect secondary fibrinolysis occurring in DIC.

SCENARIO 20 - 25yr female, menorrhagia, Hb 6.2, MCV 68, MCH 20, MCHC 22, RDW 28 (HIGH)

Q5. Most likely diagnosis: D. Iron Deficiency Anemia
Classic IDA: microcytic (MCV low) + hypochromic (MCH, MCHC low) + HIGH RDW (anisocytosis from uneven iron depletion) + menorrhagia (iron loss). Thalassemia has NORMAL RDW.
Q6. Peripheral blood smear: C. Microcytic Hypochromic
Shows: small pale RBCs, increased central pallor (>1/3 diameter), pencil cells, target cells, anisocytosis, poikilocytosis.

SCENARIO 21 - 9yr boy, fever, fatigue, bone pain, generalized lymphadenopathy, 70% blasts, anemia + thrombocytopenia + leukocytosis

Q7. Probable diagnosis: B. Acute Lymphoid Leukemia (ALL)
Age (child, peak 2-10 yrs) + lymphadenopathy + bone pain + 70% blasts = ALL. AML is less common in children. CML has minimal blasts initially with Philadelphia chromosome.
Q8. Most useful cytochemical stain: D. Periodic Acid Schiff (PAS) stain
Lymphoblasts (ALL) show block/chunky PAS positivity. Sudan black B and MPO are positive in AML (myeloid), negative in ALL. Alkaline phosphatase is used for CML/leukemoid reaction differentiation.

SCENARIO 22 - Healthy 30yr man donating blood

Q9. Disease routinely screened before donation: C. Hepatitis B
Mandatory TTI (Transfusion Transmitted Infections) screening: HBsAg, Anti-HCV, HIV 1&2, VDRL/syphilis, malaria. Diabetes/hypertension/asthma are deferral conditions, not TTI screening.
Q10. Test used to screen Hepatitis B: D. ELISA
ELISA (Enzyme-Linked Immunosorbent Assay) detects HBsAg. It is sensitive, specific, high-throughput, cost-effective - standard for blood bank screening.

SCENARIO 23 - 45yr man, yellowish eyes, PALE STOOLS, DARK URINE, bile pigments + bile salts in urine

Q11. Most likely diagnosis: B. Obstructive Jaundice
Pale stools (no bile reaching gut - duct blocked) + dark urine + bile SALTS in urine = obstructive jaundice. Bile salts appear in urine only when conjugated bilirubin backs up (conjugated = water soluble = passes in urine).
Q12. Test to detect bile salts in urine: A. Hay's test
Sulphur powder sprinkled on urine surface - if bile salts present, they lower surface tension and sulphur SINKS. If absent, sulphur FLOATS. Benedict's = glucose. Rothera's = ketones. Benzidine = occult blood.

SCENARIO 24 - 10yr girl, recurrent nosebleeds, easy bruising, family history, platelets NORMAL, BT prolonged, PT normal, aPTT mildly prolonged

Q13. Most likely diagnosis: B. Von Willebrand Disease
Classic vWD: normal platelets + prolonged BT (vWF needed for platelet adhesion) + mildly prolonged aPTT (vWF carries Factor VIII; deficiency = mild FVIII reduction) + normal PT + family history + female with mucosal bleeding.
Q14. Classically abnormal test: B. Ristocetin-induced platelet aggregation test (RIPA)
Ristocetin causes platelet agglutination ONLY if vWF is present. In vWD, vWF is absent/deficient → ristocetin FAILS to agglutinate platelets → RIPA absent or markedly reduced. This is the hallmark test for vWD.

SCENARIO 25 - 30yr female, severe anemia, needs transfusion

Q15. Most appropriate blood product: B. Packed Red Blood Cells (PRBC)
Severe isolated anemia = needs oxygen-carrying capacity = PRBCs. FFP = clotting factors. Cryoprecipitate = fibrinogen/FVIII/vWF. Platelets = thrombocytopenia. Only PRBCs correct anemia.
Q16. Storage temperature of PRBCs: B. 2-6°C
PRBCs stored at 2-6°C (refrigerated). Shelf life: 35 days in CPDA-1, 42 days in SAGM/additive solution. FFP stored at -20°C or below. Platelets stored at 20-24°C with continuous agitation.

SCENARIO 26 - 32yr female, tiredness, petechiae, Hb 6.5, WBC 2000, platelets 45,000

Q17. Reduction in all cell lines: D. Aplastic Anemia
All three cell lines reduced = Pancytopenia. The condition causing this = Aplastic Anemia (stem cell failure). The term pancytopenia describes the hematological finding.
Q18. Bone marrow in aplastic anemia: B. Hypocellular with increased fat spaces
Normal hematopoietic tissue is replaced by adipocytes (fat). Marrow cellularity <25% in severe aplastic anemia. Trephine biopsy shows "empty marrow" - fatty spaces with no hematopoietic cells.

SCENARIO 27 - 50yr male, high fever, WBC 60,000, neutrophils + bands + metamyelocytes + myelocytes, Hb normal, platelets normal, LAP score HIGH

Q19. Likely diagnosis: C. Leukemoid Reaction
KEY: LAP score is HIGH. In CML, LAP score is characteristically LOW despite massive leukocytosis. High fever + infection context + high LAP = Leukemoid Reaction (reactive neutrophilia). Normal Hb and platelets also favor leukemoid reaction.
Q20. Feature observed in leukemoid reaction: B. Toxic granules in leucocytes
Toxic granulation = coarse dark granules in neutrophil cytoplasm (increased lysosomes in response to severe infection). Also: Dohle bodies, cytoplasmic vacuolation. Bcr-Abl translocation and massive splenomegaly = CML. >20% blasts = acute leukemia.


PART 2: LONG ESSAY (10 Marks)

A 10yr old boy - severe pain, frequent vaso-occlusive crises, Hb 6.5, reticulocytes 10%, small spleen on USG, Hb electrophoresis confirms diagnosis


a) PROBABLE DIAGNOSIS: SICKLE CELL ANEMIA (HbSS Disease)

Evidence in this case:
  • Recurrent vaso-occlusive pain crises in a child
  • Severe hemolytic anemia (Hb 6.5)
  • High reticulocyte count (10%) = compensatory bone marrow response to hemolysis
  • Small spleen on USG = AUTOSPLENECTOMY (repeated splenic infarctions → fibrosis → small non-functional spleen)
  • Hb electrophoresis: >90% HbS, absent HbA, elevated HbF = confirms HbSS

b) ETIOPATHOGENESIS

Molecular Basis:
  • Point mutation in beta-globin gene on chromosome 11
  • Glutamic acid → Valine at position 6 of beta-globin chain
  • Produces HbS (alpha2-betaS2) instead of normal HbA
  • In heterozygotes (HbAS): sickle cell TRAIT - usually asymptomatic
  • In homozygotes (HbSS): sickle cell ANEMIA - full disease
Sickling Mechanism:
  1. On deoxygenation, HbS molecules undergo polymerization
  2. HbS polymers form long rod-like fibers (tactoids) that distort RBC into sickle/crescent shape
  3. Early sickling is reversible (reoxygenation restores shape)
  4. After repeated cycles, sickling becomes IRREVERSIBLE
  5. Irreversibly sickled cells: rigid, dehydrated, damaged membranes
Factors that PROMOTE sickling:
  • Hypoxia / low pO2
  • Acidosis
  • Dehydration
  • Cold temperatures
  • Infection
  • High altitude
HbF is PROTECTIVE: HbF does not polymerize with HbS. High HbF in neonates protects them from sickling. This is why symptoms start at 6 months (as HbF switches to HbA). Hydroxyurea works by INCREASING HbF.
Pathophysiological Consequences:
MechanismConsequence
Vascular occlusion by rigid sickled cellsVaso-occlusive pain crisis
Increased blood viscosityFurther occlusion
RBC destruction (splenic/intravascular)Hemolytic anemia
Repeated splenic infarctionsAutosplenectomy
Bone marrow hyperplasiaBone pain, "hair on end" skull X-ray
Pulmonary vascular occlusionAcute chest syndrome

c) LABORATORY INVESTIGATIONS

TestFinding
HemoglobinLow (6-9 g/dl)
MCV/MCH/MCHCNormal (normocytic normochromic)
Reticulocyte countHIGH (10-25%)
Peripheral blood smearSickle cells (drepanocytes), target cells, polychromasia, nucleated RBCs
Sickling test (Na metabisulfite)POSITIVE - cells sickle under induced hypoxia
Solubility test (Dithionite tube test)Positive - HbS is insoluble
Hb Electrophoresis (Gold Standard)>90% HbS, 0% HbA, elevated HbF
Serum bilirubinElevated (unconjugated) - hemolysis
LDHElevated
Serum iron/ferritinNormal or elevated (NOT iron deficient)
USG abdomenSmall fibrotic spleen (autosplenectomy)
X-ray skull"Hair-on-end" pattern (marrow hyperplasia)
X-ray spine"H-shaped vertebrae" (avascular necrosis of endplates)

d) COMPLICATIONS

1. Vaso-occlusive (Painful) Crises - most common; ischemic pain in bones, joints, abdomen, chest; triggered by infection, dehydration, cold, hypoxia
2. Acute Chest Syndrome (ACS) - fever + chest pain + new pulmonary infiltrates + hypoxia; can be fatal; requires exchange transfusion
3. Stroke/CVA - children: ischemic stroke (large vessel occlusion); 10% of children have stroke by age 20
4. Autosplenectomy - functional asplenia → increased susceptibility to encapsulated organisms (S. pneumoniae, H. influenzae, N. meningitidis); prophylactic penicillin + vaccination mandatory
5. Aplastic Crisis - Parvovirus B19 infects erythroid precursors → sudden Hb drop + reticulocytopenia; medical emergency
6. Sequestration Crisis - massive acute splenic pooling of blood → sudden Hb drop + hypovolemic shock (in children before autosplenectomy)
7. Avascular Necrosis (AVN) - femoral head most commonly affected → hip pain and disability
8. Renal Complications - papillary necrosis (medullary hypoxia), isosthenuria (inability to concentrate urine), hematuria, chronic renal failure
9. Infections - Salmonella osteomyelitis is the most common organism for bone infection in SCA (unlike normal population where Staph. aureus predominates)
10. Hemolysis-related - pigment gallstones (from chronic hemolysis), chronic leg ulcers, jaundice


PART 3: SHORT NOTES (7 x 5 = 35 Marks)


NOTE 2: BLOOD TRANSFUSION REACTIONS

Classification: Immune vs Non-Immune / Acute (<24hrs) vs Delayed (>24hrs)


ACUTE IMMUNE REACTIONS

1. Acute Hemolytic Transfusion Reaction (AHTR)
  • Most DANGEROUS acute reaction
  • Cause: ABO incompatibility (wrong blood given - clerical error)
  • Mechanism: Recipient IgM antibodies + donor RBCs → complement activation → INTRAVASCULAR hemolysis
  • Features: Fever, chills, back/flank pain, hemoglobinuria (red/brown urine), hypotension, DIC, renal failure
  • Management: STOP transfusion immediately. IV fluids. Monitor urine output. Treat DIC. Send blood to lab (repeat cross-match, DAT, urine for Hb).
2. Febrile Non-Hemolytic Transfusion Reaction (FNHTR)
  • MOST COMMON reaction
  • Cause: Recipient antibodies against donor leukocyte antigens; cytokines in stored blood
  • Features: Fever (>1°C rise), chills, rigors within 1-6 hours of transfusion
  • Management: Stop transfusion. Paracetamol. Use leukodepleted blood in future.
3. Allergic / Urticarial Reaction
  • Cause: Antibodies against donor plasma proteins
  • Features: Urticaria, itching, flushing - NO fever
  • Management: Antihistamine. Can resume transfusion slowly if mild.
4. Anaphylaxis
  • Rare. IgA-deficient recipients with anti-IgA antibodies
  • Features: Hypotension, bronchospasm, angioedema - NO fever
  • Management: STOP transfusion. Adrenaline/epinephrine. Use washed RBCs in future.

ACUTE NON-IMMUNE REACTIONS

5. TRALI (Transfusion-Related Acute Lung Injury)
  • Cause: Donor antibodies against recipient neutrophil antigens → neutrophil activation in lungs
  • Features: Acute respiratory distress within 6 hours, bilateral pulmonary infiltrates, hypoxia, NON-cardiogenic pulmonary edema
  • Management: Stop transfusion. Oxygen. Ventilatory support.
6. TACO (Transfusion-Associated Circulatory Overload)
  • Cause: Rapid transfusion / excess volume in elderly or cardiac patients
  • Features: Dyspnea, hypertension, pulmonary edema, raised JVP
  • Management: Diuretics. Slow transfusion rate. Sit patient upright.
7. Septic Reaction
  • Cause: Bacterial contamination (Yersinia enterocolitica in RBCs; Staphylococci in platelets)
  • Features: High fever, rigors, hypotension, shock
  • Management: Stop transfusion. Blood cultures (patient + bag). Broad-spectrum antibiotics.

DELAYED REACTIONS

ReactionTimingMechanismFeature
Delayed Hemolytic3-14 daysAnamnestic IgG response to minor antigensUnexplained Hb fall, positive DAT, extravascular hemolysis
TA-GvHD10-12 daysDonor T-lymphocytes attack immunocompromised hostRash, diarrhea, hepatitis, fatal pancytopenia
Post-transfusion purpura5-10 daysAntibodies destroy both donor AND recipient plateletsSudden severe thrombocytopenia
Iron overloadChronic (>100 units)Excess iron depositionLiver cirrhosis, cardiomyopathy, endocrine failure
Transfusion-transmitted infectionsVariableHBV, HCV, HIV, CMV, malariaDepends on organism

NOTE 3: SEMEN ANALYSIS

Semen analysis (seminogram) is the primary investigation for male infertility.

Collection

  • Sexual abstinence for 2-5 days before collection
  • Collected by masturbation into sterile wide-mouth container
  • Examined within 60 minutes of collection at 37°C

Normal Parameters (WHO 2021 - 6th Edition)

ParameterNormal Value
Volume≥1.4 ml
pH7.2 - 8.0
Liquefaction time≤60 minutes
Sperm concentration≥16 million/ml
Total sperm count≥39 million/ejaculate
Total motility (PR + NP)≥42%
Progressive motility≥30%
Morphology (Kruger strict)≥4% normal forms
Vitality (live sperm)≥54%
WBCs<1 million/ml

Terminology for Abnormal Results

TermDefinition
OligospermiaSperm count <16 million/ml
AzoospermiaNo sperm in ejaculate
AsthenospermiaReduced motility (<42%)
TeratospermiaAbnormal morphology (<4%)
OAT syndromeAll three defects combined
HypospermiaVolume <1.4 ml
AspermiaNo ejaculate at all
NecrospermiaAll sperm dead
Leukocytospermia>1 million WBCs/ml

Steps in Semen Analysis

  1. Macroscopic: Volume, color (whitish-grey), pH, viscosity, liquefaction time
  2. Microscopic (wet preparation): Motility assessment (progressive, non-progressive, immotile)
  3. Concentration: Improved Neubauer hemocytometer
  4. Morphology: PAP or Shorr stain - head, midpiece, tail defects assessed
  5. Vitality: Eosin-nigrosin stain (dead cells take up eosin = pink; live cells = white)
  6. MAR test / IBT: For antisperm antibodies

NOTE 4: HEREDITARY SPHEROCYTOSIS

Definition: Most common inherited hemolytic anemia in Northern Europeans. Caused by defects in RBC membrane proteins leading to spherocyte formation and extravascular hemolysis.

Genetics

  • Autosomal dominant (75%) or autosomal recessive
  • Mutations in: Ankyrin (most common, 40-65%), Band 3, spectrin, protein 4.2

Pathogenesis

  1. Deficiency of membrane skeletal proteins (ankyrin-spectrin-Band 3 complex)
  2. Membrane lipid is lost by vesiculation
  3. Surface area decreases relative to cell volume
  4. RBC becomes SPHERICAL (minimum surface area for given volume)
  5. Spherocytes are RIGID - cannot deform in splenic sinusoids
  6. Trapped and destroyed in spleen = extravascular hemolysis
  7. MCHC elevated because cells become dehydrated

Clinical Features

  • Anemia (Hb 8-12 g/dl typically)
  • Jaundice (intermittent, unconjugated)
  • Splenomegaly (splenic hyperactivity)
  • Pigment gallstones (from chronic hemolysis)
  • Aplastic crisis (Parvovirus B19)

Laboratory Findings

TestFinding
HbLow
MCHCElevated (>36 g/dl) - most important clue
MCVNormal or slightly low
RDWElevated
ReticulocytesElevated
Peripheral smearSpherocytes - small, round, dark, NO central pallor
Bilirubin (unconjugated)Elevated
Direct Coombs test (DAT)NEGATIVE - distinguishes from autoimmune hemolytic anemia
Osmotic Fragility TestINCREASED - spherocytes lyse at higher NaCl concentration
EMA binding test (flow cytometry)Reduced binding - quick diagnostic test

Treatment

  • Folic acid supplementation (ongoing)
  • Splenectomy = curative (removes site of destruction); give pneumococcal, meningococcal, Hib vaccines before splenectomy
  • Cholecystectomy if symptomatic gallstones

NOTE 5: PERNICIOUS ANEMIA

Definition: Autoimmune megaloblastic anemia caused by destruction of gastric parietal cells → deficiency of intrinsic factor (IF) → Vitamin B12 malabsorption.

Normal Vitamin B12 Absorption Pathway

  1. Dietary B12 + haptocorrin (salivary R-binder) in stomach
  2. Pancreatic proteases release B12 in duodenum
  3. B12 binds Intrinsic Factor (IF) (secreted by gastric parietal cells)
  4. B12-IF complex absorbed at terminal ileum (cubam receptor)
  5. Transported by transcobalamin II in blood

Pathogenesis of Pernicious Anemia

  • Autoimmune T-cell mediated destruction of parietal cells
  • Type I antibodies (blocking): Against IF binding site for B12 - present in 50-60% (SPECIFIC)
  • Type II antibodies (binding): Against IF-B12 complex
  • Anti-parietal cell antibodies: Present in 90% (SENSITIVE but not specific)
  • Loss of parietal cells → no IF → no B12 absorption
  • B12 deficiency → defective DNA synthesis (thymidine synthesis) → megaloblastic changes

Clinical Features

Hematological:
  • Macrocytic anemia (MCV often >120 fl)
  • Weakness, pallor, mild lemon-yellow jaundice
Gastrointestinal:
  • Glossitis (Hunter's glossitis) - smooth, beefy red, sore tongue
  • Atrophic gastritis, achlorhydria
Neurological - Subacute Combined Degeneration (SACD):
  • B12 deficiency → defective myelin synthesis (methionine pathway disrupted)
  • Demyelination of: posterior columns (vibration + position sense loss) + lateral corticospinal tracts (spastic weakness)
  • Features: Tingling/numbness in hands and feet, loss of vibration sense, positive Romberg's sign, spastic paraparesis
  • SACD does NOT occur in folate deficiency - important exam point

Laboratory Findings

TestFinding
HbLow
MCVVery high (>100 fl, often 110-140 fl)
MCHCNormal
Peripheral smearMacro-ovalocytes, hypersegmented neutrophils (>5 lobes in >5% cells)
Bone marrowMegaloblasts, giant metamyelocytes, hypercellular
Serum B12Low
Serum folateNormal
Methylmalonic acid (MMA)Elevated - specific for B12 deficiency (normal in folate deficiency)
HomocysteineElevated (raised in BOTH B12 and folate deficiency)
LDHMarkedly elevated (intramedullary hemolysis)
Anti-IF antibodiesPositive (50-60%) - specific
Anti-parietal cell antibodiesPositive (90%) - sensitive
Schilling testConfirms IF deficiency

Treatment

  • Hydroxocobalamin 1000 mcg IM daily x 7 days → weekly x 4 → monthly for LIFE
  • Oral B12 NOT effective (cannot absorb without IF)
  • Response: Reticulocytosis in 3-5 days; Hb normalizes in 8 weeks

NOTE 6: IMMUNE THROMBOCYTOPENIC PURPURA (ITP)

Definition: Acquired autoimmune disorder with isolated thrombocytopenia (<100 x 10^9/L) due to immune-mediated platelet destruction, with no identifiable underlying cause.

Classification

  • Primary ITP: No identifiable cause
  • Secondary ITP: Associated with SLE, HIV, HCV, H. pylori, drugs, CLL
  • Acute ITP: Children, self-limiting, post-viral
  • Chronic ITP: Adults (especially women 20-40 yrs), persists >12 months

Pathogenesis

  1. Autoantibodies (IgG) produced against platelet surface glycoproteins - mainly GPIIb/IIIa and GPIb/IX
  2. Antibody-coated platelets recognized by Fc receptors on SPLENIC macrophages
  3. Extravascular destruction of platelets in the spleen
  4. Antibodies may also inhibit megakaryocyte maturation → impaired platelet production
  5. T-cell dysregulation: cytotoxic T cells directly kill platelets

Clinical Features

  • Petechiae (pinpoint, non-blanching)
  • Purpura and ecchymoses (easy bruising)
  • Mucosal bleeding: epistaxis, gingival bleeding, menorrhagia
  • GI/GU bleeding in severe cases
  • Intracranial hemorrhage - rare but life-threatening (platelet count <10,000)
  • NO splenomegaly - distinguishes from hypersplenism
  • NO lymphadenopathy

Laboratory Findings

TestFinding
Platelet countLow (<100 x 10^9/L)
Hb, WBCNORMAL - isolated thrombocytopenia (KEY feature)
Peripheral smearFew large platelets; no RBC fragmentation
Bone marrowIncreased/normal megakaryocytes (peripheral destruction, not production failure)
PT, aPTTNormal
Bleeding timeProlonged

Treatment

First-line:
  • Prednisolone 1-2 mg/kg/day (reduces antibody production, blocks Fc receptors)
  • IV Immunoglobulin (IVIG) 1 g/kg x 2 days (Fc receptor blockade) - for rapid response needed
  • Anti-D immunoglobulin (in Rh-positive, non-splenectomized patients)
Second-line:
  • Splenectomy - removes main site of platelet destruction; 60-70% long-term remission
  • Rituximab (anti-CD20) - for refractory ITP
Third-line:
  • TPO receptor agonists: Romiplostim, Eltrombopag (stimulate platelet production)

NOTE 7: BENEFICENCE

Definition: Beneficence is one of the four fundamental principles of biomedical ethics (Beauchamp and Childress). It means "to do good" - the obligation to act in the best interest of the patient.

Four Principles of Biomedical Ethics

  1. Beneficence - do good
  2. Non-maleficence - do no harm (Primum non nocere)
  3. Autonomy - respect patient's right to make decisions
  4. Justice - fair distribution of healthcare resources

Components of Beneficence

  • Positive beneficence: Actively provide benefits, prevent harm, remove harm
  • Utility/proportionality: Balance benefits against risks (risk-benefit analysis)
  • Not merely "doing something good" but ensuring benefit OUTWEIGHS the risk

Applications in Hematology/Laboratory Medicine

ContextApplication of Beneficence
Blood transfusionOnly transfuse when benefit (Hb correction) outweighs risk (reactions, infections)
Bone marrow biopsyPerform only when diagnosis requires it; minimize pain
Reporting critical valuesPromptly report life-threatening values (Hb <5, platelets <10,000)
Blood donor screeningScreening for TTIs protects both donor and recipient
ChemotherapyWeigh therapeutic benefit against toxicity

Beneficence vs Non-maleficence

BeneficenceNon-maleficence
"Do good""Do no harm"
Positive obligation to actObligation to AVOID harmful actions
Example: Give appropriate transfusionExample: Do not give incompatible blood

Conflict with Autonomy

When a patient refuses beneficial treatment (e.g., Jehovah's Witness refusing blood transfusion), beneficence conflicts with autonomy. The resolution: respect informed refusal while ensuring patient understands consequences. Adult competent patients' autonomy takes precedence.

NOTE 8: ADVANTAGES AND DISADVANTAGES OF FNAC

Definition: Fine Needle Aspiration Cytology (FNAC) is a minimally invasive diagnostic procedure using a fine needle (22-25 gauge) attached to a syringe to aspirate cells from a lesion for cytological examination.

Advantages

AdvantageDetails
Minimally invasiveFine needle (22-25G), no surgical incision
QuickTakes 5-10 minutes in OPD
Rapid resultsAvailable same day to 24-48 hours
Low costNo anesthesia, no hospitalization needed
Patient complianceLess painful, less anxiety than surgery
RepeatableCan be repeated easily if sample inadequate
Pre-operative planningBenign vs. malignant before surgery
Deep lesions accessibleUSG/CT-guided FNAC for liver, lung, lymph nodes
Minimal complicationsRare: hematoma; very rare: pneumothorax (lung)
No general anesthesiaLocal or no anesthesia needed

Disadvantages

DisadvantageDetails
No tissue architectureCannot assess invasion or capsular breach
Cannot diagnose in-situ carcinomaRequires tissue section for this
Sampling errorMay miss lesion in heterogeneous tumors
Operator dependentQuality depends on technique and expertise
Cannot grade tumorsGrading requires histological architecture
Poor yield from fibrotic lesionsScirrhous breast tumors, fibrotic nodes → dry tap
Limited lymphoma subtypingCore biopsy + IHC needed for proper lymphoma classification
False negativesHypocellular/necrotic lesions misdiagnosed as benign
Inadequate sampleCystic lesions yield only fluid

FNAC vs Core Biopsy vs Excision Biopsy

ParameterFNACCore BiopsyExcision Biopsy
InvasivenessLeastModerateMost
Tissue architectureNOYESYES
CostLowModerateHigh
SpeedFastestModerateSlowest
Lymphoma subtypingPoorGoodExcellent


PART 4: APPLIED QUESTIONS (4 x 5 = 20 Marks)


Q9: 6yr old boy, recurrent painful knee swelling after minor trauma, platelet count NORMAL, bleeding time NORMAL, aPTT PROLONGED

a) Likely Diagnosis: HEMOPHILIA A (Factor VIII Deficiency)

b) Pathogenesis and Laboratory Findings

Genetics:
  • X-linked recessive (gene: F8, Xq28)
  • Males affected; females are carriers
  • Most common mutation: inversion of intron 22 (in ~45% of severe hemophilia A)
  • About 30% are new mutations (no family history)
Pathogenesis:
Normal coagulation requires Factor VIII as a COFACTOR in the intrinsic (contact activation) pathway:
XIIa → XIa → IXa + VIIIa (TENASE complex) → Xa → Thrombin → Fibrin
  • Factor VIIIa acts as cofactor for Factor IXa in the tenase complex
  • This complex activates Factor X → common pathway → thrombin → fibrin clot
  • In Hemophilia A: Factor VIII is absent/markedly reduced
  • Tenase complex cannot form properly
  • Factor X activation is severely impaired
  • Insufficient thrombin → inadequate fibrin clot
  • Primary hemostasis (platelet plug via vWF) is INTACT
  • Secondary hemostasis (fibrin reinforcement) is DEFECTIVE
Why joint bleeds (hemarthroses)? Synovial fluid lacks tissue factor (TF), so the extrinsic pathway cannot compensate for the intrinsic pathway defect. Joints are therefore the most vulnerable site. Repeated hemarthroses → iron deposition → synovitis → cartilage destruction → hemophilic arthropathy (chronic disability).
Laboratory Findings:
TestResultReason
Platelet countNORMALPlatelets unaffected
Bleeding time (BT)NORMALPrimary hemostasis intact
Prothrombin time (PT)NORMALExtrinsic pathway (VII, X, V, II, I) intact
aPTTPROLONGEDIntrinsic pathway defect
Thrombin timeNormal
Factor VIII assayLOWConfirms diagnosis and severity
vWF antigenNormalDistinguishes from vWD
RIPA (ristocetin)Normal
Severity Classification:
SeverityFactor VIIIClinical Features
Severe (<1%)<1 IU/dlSpontaneous hemarthroses and muscle bleeds
Moderate (1-5%)1-5 IU/dlBleeds with minor trauma
Mild (5-40%)5-40 IU/dlBleeds only with surgery/major trauma
Treatment:
  • Factor VIII concentrate replacement (recombinant preferred)
  • Prophylactic infusions 3x/week in severe disease
  • DDAVP (desmopressin) for mild hemophilia A (releases stored vWF-FVIII)
  • Emicizumab (bispecific antibody) - new preventive treatment

Q10: 55yr man, weight loss, MASSIVE SPLENOMEGALY, Hb 9.5, WBC 93,000/cmm, platelets 1.7 lakhs, peripheral smear shows granulocytes at ALL stages of maturation WITH BASOPHILIA

a) Diagnosis: CHRONIC MYELOID LEUKEMIA (CML)

b) Pathogenesis

Molecular Basis - Philadelphia Chromosome:
  • Reciprocal translocation: t(9;22)(q34;q11)
  • BCR gene (chromosome 22) fuses with ABL1 gene (chromosome 9)
  • Creates BCR-ABL1 fusion gene on the derivative chromosome 22 (Philadelphia chromosome)
  • Encodes p210 BCR-ABL1 protein - a constitutively active tyrosine kinase
  • This kinase continuously activates: RAS/MAPK, JAK/STAT, PI3K/AKT pathways
  • Results in: Uncontrolled myeloid proliferation + inhibition of apoptosis + impaired differentiation
Three Phases of CML:
  1. Chronic Phase (years): Indolent; well-controlled with TKI
  2. Accelerated Phase: Blasts 10-19%, increasing basophilia, clonal evolution
  3. Blast Crisis: >20% blasts (myeloid or lymphoid) - resembles acute leukemia; very poor prognosis

c) Peripheral Smear Findings in CML

The peripheral smear is HIGHLY characteristic:
  1. Marked leukocytosis - WBC typically 50,000-200,000/cmm
  2. Full left shift (myeloid spectrum): myeloblasts → promyelocytes → myelocytes → metamyelocytes → band forms → mature neutrophils. "Myelocyte bulge" - peak at myelocyte stage
  3. BASOPHILIA - absolute basophilia is the HALLMARK of CML (distinguishes from leukemoid reaction)
  4. Eosinophilia - also present
  5. Thrombocytosis - platelets often elevated (>400,000) in early CML
  6. Minimal blasts (<5%) in chronic phase
  7. No toxic granulation or Dohle bodies (unlike leukemoid reaction)
CML vs Leukemoid Reaction:
FeatureCMLLeukemoid Reaction
LAP scoreLOW/absentHIGH
BasophiliaPresentAbsent
Philadelphia chromosomePresent (t(9;22))Absent
SplenomegalyMassiveAbsent/mild
Toxic granulationAbsentPresent
ContextInsidiousInfection/sepsis
Investigations:
  • Cytogenetics: Philadelphia chromosome (karyotype)
  • FISH: BCR-ABL1 fusion - sensitive
  • RT-PCR (quantitative): BCR-ABL1 transcript levels - monitors treatment response
  • Bone marrow trephine: Hypercellular, myeloid hyperplasia, increased reticulin
Treatment:
  • Imatinib (1st generation TKI) - transformed CML from fatal disease to chronic manageable condition
  • Dasatinib, Nilotinib (2nd gen TKI) for resistance/intolerance
  • Ponatinib, Asciminib (3rd gen TKI)
  • Allogenic stem cell transplant for blast crisis or TKI failure

Q11: 30yr man, weakness, fever, NIGHT SWEATS, weight loss 1yr, multiple RUBBERY DISCRETE lymph nodes in neck, biopsy shows OWL EYE cells

a) Diagnosis: HODGKIN'S LYMPHOMA (Classical)

b) Classification, Gross and Microscopy

Pathognomonic finding: REED-STERNBERG (RS) CELLS = "Owl Eye" cells
RS Cell description:
  • Large binucleated or multinucleated cell
  • Each nucleus contains a LARGE prominent EOSINOPHILIC NUCLEOLUS resembling an owl's eye
  • Seen within a reactive inflammatory background
  • RS cells are the NEOPLASTIC cells (clonal B-cell origin)
  • CD30 positive, CD15 positive, CD45 negative, CD20 usually negative
  • RS cells are a MINORITY (<5%) - surrounded by reactive inflammatory cells

CLASSIFICATION (WHO - 5 types):

Classical Hodgkin Lymphoma (4 subtypes):
1. Nodular Sclerosis (NS) - Most common (65-70%)
  • Young females, mediastinal mass
  • Variant RS cells: LACUNAR CELLS (retraction artifact in formalin)
  • BROAD COLLAGEN BANDS dividing lymph node into nodules
  • EBV association: Low (<10%)
  • Good prognosis
2. Mixed Cellularity (MC) - Second most common (20-25%)
  • Older adults, males > females
  • Classic RS cells in MIXED inflammatory background (eosinophils, plasma cells, lymphocytes, histiocytes)
  • Diffuse effacement of architecture
  • EBV association: HIGH (70%)
  • Intermediate prognosis
3. Lymphocyte Rich (LR) - Rare (5%)
  • Background predominantly lymphocytes
  • Classic RS cells sparse
  • Good prognosis
4. Lymphocyte Depleted (LD) - Rarest (<1%)
  • Elderly, HIV patients
  • Many RS cells, few lymphocytes
  • EBV association: Very high
  • Worst prognosis
Non-Classical HL:
5. Nodular Lymphocyte Predominant HL (NLPHL)
  • Neoplastic cells = "POPCORN CELLS" (LP cells / L&H cells)
  • CD20+, CD30-, CD15- (opposite of classical HL)
  • EBV negative
  • Best prognosis

GROSS APPEARANCE

  • Lymph nodes: Enlarged, rubbery, discrete, non-tender
  • Cut surface: Gray-white, "fish flesh" appearance
  • Nodular sclerosis: White fibrous bands visible on gross cut section
  • Contiguous spread: HL spreads in PREDICTABLE contiguous pattern (cervical → mediastinal → para-aortic → spleen)

MICROSCOPY

Three key microscopic elements:
  1. Reed-Sternberg cells (pathognomonic)
  2. Variant RS cells specific to subtype (lacunar cells in NS; popcorn cells in NLPHL)
  3. Background inflammatory infiltrate (varies by subtype)
IHC Panel for Classical HL:
  • CD30 positive (membrane + Golgi pattern)
  • CD15 positive
  • CD45 (LCA) negative
  • PAX5 weakly positive
  • CD20 usually negative

STAGING (Ann Arbor / Lugano)

  • Stage I: Single lymph node region or single extralymphatic site
  • Stage II: Two or more regions, SAME side of diaphragm
  • Stage III: Regions on BOTH sides of diaphragm
  • Stage IV: Disseminated extranodal involvement
B symptoms (poor prognosis): Fever >38°C, drenching night sweats, weight loss >10% in 6 months
Treatment: ABVD (Adriamycin + Bleomycin + Vinblastine + Dacarbazine) ± radiotherapy

Q12: 62yr man, chronic back pain, weakness 3 months, X-ray skull shows MULTIPLE PUNCHED-OUT LYTIC LESIONS, anemia, HYPERCALCEMIA, raised creatinine, raised ESR

a) Probable Diagnosis: MULTIPLE MYELOMA (MM)

b) Pathogenesis and Lab Diagnosis

Definition: Multiple myeloma is a malignancy of PLASMA CELLS (terminally differentiated B cells) in bone marrow, secreting a monoclonal immunoglobulin (M-protein).
Pathogenesis:
Step 1 - Plasma cell transformation: Malignant plasma cells accumulate cytogenetic abnormalities: t(4;14), t(14;16), del17p, del13q. These drive uncontrolled proliferation and resistance to apoptosis.
Step 2 - Marrow infiltration:
10% clonal plasma cells in bone marrow (symptomatic MM) → normal hematopoiesis suppressed → anemia, leukopenia, thrombocytopenia.
Step 3 - M-protein production: All malignant plasma cells produce IDENTICAL immunoglobulin (monoclonal = M-protein). Most common: IgG > IgA. Free light chains only = Bence Jones myeloma.
Step 4 - Bone destruction (lytic lesions):
  • Myeloma cells produce RANKL (receptor activator of NF-kB ligand) and inhibit OPG (osteoprotegerin)
  • RANKL activates OSTEOCLASTS → lytic bone destruction
  • NO compensatory osteoblast activation → pure lytic lesions (no sclerosis)
  • "Punched-out" lytic lesions on X-ray (skull, spine, pelvis, ribs)
  • Osteolysis → HYPERCALCEMIA
Step 5 - Renal failure (Myeloma kidney):
  • Free light chains (Bence Jones proteins) filtered by glomeruli, precipitate in tubules
  • Cast nephropathy → tubular obstruction and inflammation
  • Also: hypercalcemia nephropathy, amyloidosis, contrast nephrotoxicity
Step 6 - Immune paresis: Normal immunoglobulin production suppressed → recurrent infections (especially pneumococcal pneumonia)

CRAB Criteria (Symptomatic Myeloma):

  • C - Calcium elevated (>11.5 mg/dl or >1 mg/dl above upper normal)
  • R - Renal failure (creatinine >2 mg/dl)
  • A - Anemia (Hb <10 g/dl)
  • B - Bone lesions (lytic lesions/osteoporosis/pathological fractures)

LABORATORY DIAGNOSIS

InvestigationFinding
CBCNormocytic normochromic anemia; normal WBC/platelets initially
ESRVery high (often >100 mm/hr) - due to elevated plasma proteins
Peripheral smearRouleaux formation (RBCs stacked like coins from elevated globulins)
Serum calciumElevated
Serum creatinineElevated
Serum proteinElevated total protein; low albumin; HIGH globulin fraction
SPEP (Serum Protein Electrophoresis)M-spike (M-band/paraprotein) in gamma or beta region
Immunofixation (IFE)Identifies and types M-protein (IgG kappa most common)
Serum Free Light ChainsElevated; abnormal kappa/lambda ratio
24hr urine electrophoresisBence Jones protein (free light chains in urine)
Serum beta-2 microglobulinElevated (ISS staging marker)
LDHElevated (tumor burden marker)
Bone marrow biopsy>10% clonal plasma cells (eccentric nucleus, clock-face chromatin, perinuclear hof)
Skeletal survey X-rayPunched-out lytic lesions in skull, spine, ribs, pelvis ("moth-eaten" appearance)
MRI spineBetter than X-ray; detects compression fractures early
Treatment:
  • VRd: Bortezomib (proteasome inhibitor) + Lenalidomide + Dexamethasone
  • Autologous Stem Cell Transplantation (ASCT) in eligible patients (<65-70 yrs)
  • Bisphosphonates (zoledronic acid) for bone disease prevention
  • Daratumumab (anti-CD38 monoclonal antibody) - highly effective newer agent


PART 5: REASONING QUESTIONS (5 x 3 = 15 Marks)


Q13: Role of Anticoagulants in Hematology Lab - Name all anticoagulants and their uses

Why Anticoagulants Are Needed

Blood begins clotting within seconds of leaving vessels. Anticoagulants preserve blood in liquid state for laboratory testing by inhibiting coagulation.

1. EDTA (Ethylenediamine Tetraacetic Acid)

  • Tube: Purple/lavender top
  • Mechanism: Chelates (binds/sequesters) calcium ions irreversibly → blocks all calcium-dependent coagulation steps
  • Uses:
    • CBC / Full Blood Count (gold standard anticoagulant for CBC)
    • Peripheral blood smear
    • Reticulocyte count
    • HbA1c
    • Blood grouping and cross-matching
    • Coombs test (DAT/IAT)
    • CD4/CD8 counts (HIV monitoring)
    • DNA studies
  • Note: Causes pseudo-thrombocytopenia (platelet clumping in some patients) - if suspected, repeat with citrate tube

2. Sodium Citrate (3.2%)

  • Tube: Blue top
  • Mechanism: Chelates calcium REVERSIBLY → anticoagulation can be reversed by adding calcium back in the assay
  • Critical ratio: 9 parts blood : 1 part citrate (tube must be filled exactly)
  • Uses:
    • PT/INR - most important
    • aPTT
    • All coagulation studies
    • Fibrinogen estimation
    • D-dimer assay
    • ESR (Westergren method): 4 parts blood : 1 part citrate
  • Why citrate and not EDTA for coagulation tests? Because citrate chelation is reversible - calcium can be added back to activate clotting in the PT/aPTT assay.

3. Heparin (Lithium heparin / Sodium heparin)

  • Tube: Green top
  • Mechanism: Activates Antithrombin III → inhibits thrombin (Factor IIa), Factor Xa, IXa, XIa, XIIa
  • Uses:
    • Plasma chemistry tests
    • Chromosomal studies (cytogenetics/karyotyping) - anticoagulant of choice for lymphocyte cultures
    • Arterial blood gas (sodium heparin syringe)
    • Plasma osmolality
  • NOT used for CBC - causes cell clumping and poor staining

4. Fluoride-Oxalate

  • Tube: Grey top
  • Two components:
    • Sodium fluoride: Inhibits enolase enzyme → blocks glycolysis → preserves glucose for 24+ hours
    • Potassium oxalate: Precipitates calcium as calcium oxalate → anticoagulation
  • Uses:
    • Blood glucose estimation
    • Glucose Tolerance Test (GTT)
    • Lactate measurement

5. ACD (Acid Citrate Dextrose)

  • Tube: Yellow top / blood bag (solution A or B)
  • Mechanism: Citrate (anticoagulation) + Acid (lowers pH, reduces ATP consumption) + Dextrose (energy for RBC metabolism)
  • Uses:
    • Blood banking - storage of whole blood
    • HLA typing
    • DNA studies
    • Paternity testing
    • Lymphocyte preservation

6. CPDA-1 (Citrate Phosphate Dextrose Adenine)

  • Used in: Blood collection bags
  • Mechanism: Citrate (anticoagulant + preservative) + Phosphate (maintains 2,3-DPG and ATP) + Dextrose (energy) + Adenine (ATP resynthesis)
  • Uses:
    • Blood banking: Storage of PRBCs for 35 days at 2-6°C
    • Most widely used blood bag anticoagulant-preservative solution

Summary Table

AnticoagulantTube ColorMechanismPrimary Use
EDTAPurpleCa²⁺ chelation (irreversible)CBC, peripheral smear
Sodium Citrate 3.2%BlueCa²⁺ chelation (reversible)PT, aPTT, coagulation tests
Lithium HeparinGreenActivates AT-IIIPlasma chemistry, cytogenetics
Fluoride-OxalateGreyCa²⁺ precipitation + glycolysis inhibitionBlood glucose
ACDYellowCitrate + acid + dextroseBlood banking, DNA studies
CPDA-1Blood bagCitrate + phosphate + dextrose + adeninePRBC storage (35 days)

Q14: Heat Coagulation Test for Protein - Why Only Upper Third Heated; Principle; Causes of Proteinuria

Why ONLY the Upper Third is Heated

The lower two-thirds of the tube are left unheated to serve as a CONTROL.
Detailed reason:
  1. When the upper third is heated, any turbidity that appears must be compared to the CLEAR lower portion to confirm it is genuine
  2. Phosphates and carbonates in urine also precipitate on heating → these can give false positive turbidity
  3. To distinguish: 2-3 drops of 1% acetic acid are added to the turbid upper portion
    • Protein turbidity: PERSISTS or INCREASES on adding acetic acid (acetic acid brings pH toward isoelectric point of albumin → maximum precipitation)
    • Phosphate/carbonate turbidity: DISSOLVES on adding acetic acid
  4. The unheated lower portion confirms that baseline urine is clear (rules out pre-existing turbidity from phosphates, cells, bacteria)

Principle of Heat Coagulation Test

Proteins are denatured and precipitated by heat.
  1. Heat disrupts hydrogen bonds and hydrophobic interactions maintaining protein tertiary structure
  2. Protein chains unfold (denaturation) - exposing hydrophobic core regions
  3. Multiple unfolded proteins interact via exposed hydrophobic regions → AGGREGATION
  4. Aggregated proteins precipitate → visible turbidity
  5. Precipitation is maximum at the protein's isoelectric point (zero net charge = minimum solubility)
  6. Acetic acid adjusts urine pH toward albumin's isoelectric point (pI ~4.7) → maximizes albumin precipitation
Procedure:
  1. Take clear urine (centrifuge if turbid)
  2. Fill 3/4 of test tube
  3. Hold at 45° and heat ONLY upper 1/3 over flame
  4. Observe for turbidity/precipitate
  5. Add 2-3 drops 1% acetic acid
  6. Interpret and grade:
    • Trace: Faint haze
    • 1+: Definite white cloud
    • 2+: Heavy flocculation
    • 3-4+: Solid coagulum

Causes of Proteinuria

A. Glomerular Proteinuria (most common)
  • Loss of glomerular filtration barrier
  • Causes: Nephrotic syndrome (minimal change disease, membranous nephropathy, FSGS, diabetic nephropathy), glomerulonephritis
  • Predominantly albumin (>3.5 g/day in nephrotic syndrome)
B. Tubular Proteinuria
  • Impaired tubular reabsorption of low molecular weight proteins
  • Causes: Acute tubular necrosis, Fanconi syndrome, heavy metal poisoning, aminoglycoside toxicity
  • LMW proteins: beta-2 microglobulin, alpha-1 microglobulin
C. Overflow Proteinuria
  • Plasma proteins exceed tubular reabsorptive capacity
  • Causes: Multiple myeloma (Bence Jones = free light chains), myoglobinuria (rhabdomyolysis), hemoglobinuria (hemolysis)
D. Postrenal/Secretory Proteinuria
  • Protein added to urine below the glomerulus
  • Causes: UTI, pyelonephritis, urogenital tumors
E. Functional/Physiological Proteinuria (benign, transient)
  • Orthostatic/postural proteinuria (common in young men, resolves lying down)
  • Fever, vigorous exercise, emotional stress, cold exposure

Q15: CSF forms a COBWEB CLOT on standing from suspected meningitis

a) Diagnosis: TUBERCULOUS MENINGITIS

A cobweb clot (delicate pellicle/filmy clot) forming when CSF is left standing is PATHOGNOMONIC of Tuberculous Meningitis.
Why cobweb forms:
  • TB meningitis causes markedly elevated CSF protein (especially fibrinogen)
  • On standing, fibrinogen polymerizes into fibrin
  • Forms a delicate cobweb-like clot (pellicle) at the top of the tube
  • This pellicle contains MTB bacilli → smear the clot for AFB staining (increases AFB detection)

b) Differentiation: TB Meningitis vs Pyogenic Meningitis

FeatureTB MeningitisPyogenic Meningitis
Causative organismMycobacterium tuberculosisN. meningitidis, S. pneumoniae, H. influenzae, Listeria
OnsetSubacute/chronic (days-weeks)Acute/rapid (hours-days)
CSF appearanceOpalescent/slightly turbid; cobweb clot forms on standingFrankly turbid or purulent; no cobweb clot
CSF pressureElevatedMarkedly elevated
CSF cells50-500; LYMPHOCYTES predominateHundreds-thousands; NEUTROPHILS (PMNs) predominate
CSF glucoseLow (ratio <0.5)Very low (often undetectable)
CSF proteinHigh (100-500 mg/dl)High
Gram stainNegativePositive in 60-90%
AFB stainPositive (may be seen)Negative
CultureMTB culture (takes 4-8 weeks)Bacterial culture (24-48 hours)
ADA (Adenosine Deaminase)Elevated (>10 U/L)Normal
PCRMTB PCR positiveOrganism-specific PCR
CSF chlorideDecreasedDecreased
India inkNegative (positive in Cryptococcal meningitis)Negative
TreatmentHRZE x 2 months + HR x 7-10 months + dexamethasoneCeftriaxone ± Vancomycin + Dexamethasone (empiric)

Q16: 6-month-old baby, pallor, INCREASED reticulocyte count

a) Reasoning and Causes for High Reticulocyte Count

Reasoning:
  • Reticulocytes are immature RBCs retaining residual ribosomal RNA
  • Normal range: 0.5-2.5% in adults; 2.5-6.5% in neonates
  • Elevated reticulocyte count = REGENERATIVE anemia = bone marrow is actively producing RBCs in response to increased demand
  • Elevated retics + pallor = hemolysis OR blood loss (marrow compensating)
In a 6-month-old specifically:
  • At birth: predominantly HbF; switch to HbA begins at 3-6 months
  • Conditions presenting at this age: Thalassemia major, G6PD deficiency triggered by infection, hereditary spherocytosis, hemolytic disease of newborn (if severe)
Causes of High Reticulocyte Count:
CategoryExamples
Hemolytic anemiasHereditary spherocytosis, G6PD deficiency, PK deficiency, ABO/Rh hemolytic disease of newborn, sickle cell anemia, thalassemia intermedia
Acute blood lossTrauma, GI bleed, intracranial hemorrhage in neonates
Treatment responseIron deficiency responding to iron; B12/folate deficiency responding to treatment (reticulocyte crisis at day 5-7)
Post-splenectomyTransient reticulocytosis

b) Stains Used for Reticulocytes

Reticulocytes require SUPRAVITAL STAINING - dye is added to LIVING (unfixed) blood cells to precipitate residual RNA as visible granules/filaments.
1. NEW METHYLENE BLUE (NMB) - Most preferred, WHO recommended
  • Equal volumes of blood + NMB solution → incubate 10-15 min at 37°C → smear
  • Residual RNA precipitates as BLUE-GREEN granules/filaments (reticulum)
  • Also demonstrates: HbH inclusions (multiple small blue dots = golf ball appearance) in HbH disease; Heinz bodies
2. BRILLIANT CRESYL BLUE (BCB)
  • Similar principle to NMB; older method still used in some centers
  • Stains RNA as blue reticulum
3. ACRIDINE ORANGE (Fluorescent)
  • Binds nucleic acids; visualized under fluorescence microscope
  • More sensitive; used in automated analyzers
  • Orange fluorescence indicates RNA content
4. Automated Flow Cytometry (Modern gold standard)
  • Fluorescent dyes: Thiazole orange or Oxazine 750
  • Provides: Absolute reticulocyte count + Immature Reticulocyte Fraction (IRF) - best marker of bone marrow activity
Important Formulas:
Corrected Reticulocyte Count (CRC) = Reticulocyte % × (Patient Hb / Normal Hb)
Reticulocyte Production Index (RPI) = CRC / Maturation factor
  • RPI >3 = adequate regenerative response (hemolysis/blood loss)
  • RPI <2 = hypoproliferative (marrow failure, nutritional deficiency)

Q17: Why is Pap Smear Recommended as Routine Screening? Describe All Normal Cells Seen

Why Pap Smear is Recommended as Routine Screening

  1. Cervical cancer is preventable: Pap smear detects precancerous lesions (CIN - Cervical Intraepithelial Neoplasia) YEARS before they progress to invasive cancer
  2. HPV causation: ~100% of cervical cancers caused by high-risk HPV (types 16, 18, 31, 33, 45). Pap smear detects HPV-related cytological changes (koilocytes = pathognomonic of HPV infection)
  3. Long premalignant phase (10-15 years):
    • Normal → CIN I → CIN II → CIN III → Carcinoma in situ → Invasive cancer
    • This 10-15 year window allows DETECTION and TREATMENT before malignancy
  4. Simple, inexpensive, non-invasive: Performed in OPD without anesthesia; cost-effective for mass screening
  5. Proven mortality reduction: Mass Pap screening reduced cervical cancer mortality by >70% in countries with organized programs
  6. Detects other conditions: Vaginal infections (Trichomonas, Candida, bacterial vaginosis), endometrial cells (flag for endometrial pathology in postmenopausal women), inflammatory changes
Screening Recommendations:
  • Start at age 21 (or within 3 years of first sexual activity)
  • Cytology alone: every 3 years
  • Co-testing with HPV DNA: every 5 years (age 30-65)
  • Stop at age 65 with adequate prior negative screening
Collection:
  • Ectocervix: Ayre's spatula (samples transformation zone)
  • Endocervix: Cytobrush
  • Fix immediately in 95% ethyl alcohol (conventional) OR liquid-based cytology (ThinPrep/SurePath - preferred)

Normal Cells Seen in Pap Smear

A. SQUAMOUS EPITHELIAL CELLS (Most abundant)
Squamous maturation is governed by ESTROGEN (more estrogen = more superficial maturation):
1. Superficial Cells (most mature)
  • Origin: Uppermost squamous layer
  • Size: Large, flat, polygonal
  • Nucleus: PYKNOTIC (small, dark, condensed, <6 microns) - hallmark
  • Cytoplasm: EOSINOPHILIC (pink/orange) - keratin
  • Seen predominantly in: Proliferative (follicular) phase; high estrogen states
  • Karyopyknotic index (KPI) = % superficial cells = estrogen index
2. Intermediate Cells
  • Origin: Intermediate squamous layer
  • Size: Large, polygonal (slightly smaller than superficial)
  • Nucleus: VESICULAR (open, pale, larger than superficial cell nucleus)
  • Cytoplasm: CYANOPHILIC (blue-green); may contain glycogen vacuoles
  • Navicular cells = boat-shaped intermediate cells with folded edges (seen in pregnancy and luteal phase)
  • Seen predominantly in: Luteal phase, pregnancy, progestogen influence
3. Parabasal Cells
  • Origin: Lower squamous layers
  • Size: Smaller, oval/round
  • Nucleus: Large relative to cytoplasm, vesicular
  • Cytoplasm: Cyanophilic, dense, scant
  • Seen predominantly in: Estrogen deficiency (menopause, postpartum, breastfeeding) = atrophic smear
  • Normal in postmenopausal women
4. Basal Cells (rarely seen)
  • Smallest squamous cells
  • Large nucleus, scant cytoplasm
  • Seen only in severe atrophy

B. ENDOCERVICAL CELLS
  • Origin: Columnar epithelium lining endocervical canal
  • Appearance: Tall columnar cells arranged in HONEYCOMB or PICKET-FENCE pattern in sheets
  • Nucleus: Small, round, basal
  • Cytoplasm: Pale, foamy, mucin-containing (mucin secretion)
  • Single cells appear "goblet cell-like"
  • Presence on smear = adequate sampling (transformation zone sampled)

C. METAPLASTIC CELLS (Squamous Metaplasia)
  • Origin: Transformation zone (squamocolumnar junction) - most important area to sample
  • Appearance: Round/oval cells, intermediate between squamous and columnar
  • Dense cytoplasm, may have cytoplasmic projections ("spider cells" or "caudate cells")
  • Immature metaplastic cells have high N/C ratio
  • Normal finding - represents physiological replacement of columnar by squamous epithelium

D. ENDOMETRIAL CELLS
  • Small, round cells in tight clusters
  • "Two-cell pattern": Epithelial cells + stromal cells together
  • High N/C ratio
  • Normal to see in first 10-12 days of menstrual cycle
  • Abnormal if seen after day 12 in postmenopausal women (requires endometrial investigation)

E. INFLAMMATORY CELLS
  • Neutrophils (polymorphs): Small, multilobed nuclei; normal in small numbers; increased in infection/inflammation
  • Histiocytes (macrophages): Bean-shaped/kidney-shaped nucleus; vacuolated cytoplasm; single cells; normal finding
  • Lymphocytes: Rare; increased in follicular cervicitis (lymphoid follicles in submucosa)

F. NORMAL FLORA
  • Lactobacilli (Doderlein's bacilli): Large plump bacilli; normal vaginal flora; indicate healthy acidic environment (pH 3.8-4.5); produce lactic acid from glycogen in intermediate cells

Reporting System - Bethesda System 2014

CategoryMeaning
NILMNegative for Intraepithelial Lesion or Malignancy (NORMAL)
ASC-USAtypical squamous cells of undetermined significance
ASC-HAtypical squamous cells - cannot exclude HSIL
LSILLow-grade SIL (CIN 1, HPV effect, koilocytes)
HSILHigh-grade SIL (CIN 2, CIN 3, CIS)
SCCSquamous cell carcinoma
AGCAtypical glandular cells
AISAdenocarcinoma in situ
AdenocarcinomaEndocervical or endometrial

END OF COMPLETE ANSWERS

All questions have been answered in full examination distinction-level detail. The answers cover every MCQ with reasoning, the full long essay on sickle cell disease, all seven short notes, all four applied clinical questions, and all five reasoning questions.
This is a shared conversation. Sign in to Orris to start your own chat.